The Meibomian Blepharitis drugs in development market research report provides comprehensive information on the therapeutics under development for Meibomian Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Meibomian Blepharitis. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Meibomian Blepharitis and features dormant and discontinued products.

GlobalData tracks five drugs in development for Meibomian Blepharitis by six companies/universities/institutes. The top development phase for Meibomian Blepharitis is phase ii with three drugs in that stage. The Meibomian Blepharitis pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Meibomian Blepharitis pipeline products market are: Santen Pharmaceutical, Alcon and Senju Pharmaceutical.

The key targets in the Meibomian Blepharitis pipeline products market include Janus Kinase (JAK or EC 2.7.10.2), IkappaB Kinase (IKK or EC 2.7.11.10), and Serine/Threonine Protein Kinase mTOR (FK506 Binding Protein 12 Rapamycin Complex Associated Protein 1 or FKBP12 Rapamycin Complex Associated Protein or Mammalian Target Of Rapamycin or Mechanistic Target Of Rapamycin or Rapamycin And FKBP12 Target 1 or Rapamycin Target Protein 1 or MTOR or EC 2.7.11.1).

The key mechanisms of action in the Meibomian Blepharitis pipeline product include Serine/Threonine Protein Kinase mTOR (FK506 Binding Protein 12 Rapamycin Complex Associated Protein 1 or FKBP12 Rapamycin Complex Associated Protein or Mammalian Target Of Rapamycin or Mechanistic Target Of Rapamycin or Rapamycin And FKBP12 Target 1 or Ra with one drug in Phase II. The Meibomian Blepharitis pipeline products include four routes of administration with the top ROA being Ophthalmic and one key molecule types in the Meibomian Blepharitis pipeline products market including Small Molecule.

Meibomian Blepharitis overview

Meibomian blepharitis or Meibomian gland dysfunction (MGD) is a condition that causes low-grade inflammation of the eyelids. It can also lead to obstruction of the oil glands in the eyelid. It is caused by high cholesterol and triglycerides, allergic conjunctivitis and other eye diseases, inflamed or damaged eyelid or cornea, bacterial infection, and autoimmune diseases like rosacea, lupus, rheumatoid arthritis, and Sjögren’s syndrome. Symptoms include itching, burning sensation, redness, irritation, soreness of eyes, eyelid edema, and foreign body sensation. Treatment options include warm compresses, antibiotic or steroid eye drops, artificial tear eye drops, and oral antibiotics.

For a complete picture of Meibomian Blepharitis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.